Find out all about your favorite commercial!

Advertisers

Advertisers of the Vanda Pharmaceuticals TV Spot, 'Smith-Magenis Syndrome'

Vanda Pharmaceuticals TV commercial - Smith-Magenis Syndrome
Vanda Pharmaceuticals

Vanda Pharmaceuticals: A Brief OverviewVanda Pharmaceuticals is a global biopharmaceutical company focused on the development , commercialization, and delivery of innovative therapies to address high...

What the Vanda Pharmaceuticals TV commercial - Smith-Magenis Syndrome is about.

Vanda Pharmaceuticals TV commercial - Smith-Magenis Syndrome

Title: Vanda Pharmaceuticals TV Spot Sheds Light on Smith-Magenis Syndrome

Introduction:In a bid to raise awareness about Smith-Magenis Syndrome (SMS), a rare genetic disorder that affects approximately 1 in every 25,000 individuals, Vanda Pharmaceuticals has unveiled a powerful and informative TV spot. With a heartfelt approach, this commercial strives to shed light on the challenges faced by those living with SMS while also instilling hope for a brighter future. Let's delve into the details of this thought-provoking TV spot.

TV Spot Description:The Vanda Pharmaceuticals TV spot begins with a soft, captivating melody playing in the background. The screen comes alive with vibrant colors as it showcases different moments from the lives of individuals with Smith-Magenis Syndrome. The commercial strategically uses real-life footage, depicting individuals of varying ages engaging in everyday activities.

As the commercial progresses, the focus narrows in on the unique features and characteristics of SMS. It highlights the difficulties faced by individuals with SMS in expressing emotions, communicating effectively, and maintaining regular sleep patterns. The TV spot effectively showcases the challenges faced by individuals with SMS while also highlighting their resilience and strength.

The Voiceover:A compassionate and empathetic voiceover accompanies the visual montage. The voiceover artist conveys a sense of understanding and offers reassurance to both individuals with SMS and their families. The voiceover beautifully articulates the complexities of living with Smith-Magenis Syndrome, emphasizing the need for empathy, support, and understanding within society.

The Message:As the commercial reaches its crescendo, the visuals transition to scenes of hope and progress. The voiceover emphasizes the importance of raising awareness, advocating for research, and supporting individuals with SMS and their families. The commercial encourages viewers to visit Vanda Pharmaceuticals' website for more information on Smith-Magenis Syndrome and the available resources - a call to action intended to empower those touched by SMS to seek knowledge, support, and communities dedicated to their wellbeing.

The Impact:Vanda Pharmaceuticals' TV spot on Smith-Magenis Syndrome is a powerful campaign that seizes the opportunity to educate the general public about this often misunderstood genetic disorder. By bringing visibility to the challenges faced by individuals with SMS while emphasizing the potential for a hopeful future, the commercial aims to create a more inclusive and compassionate society.

Conclusion:Through their TV spot, Vanda Pharmaceuticals has successfully raised awareness about Smith-Magenis Syndrome, shedding light on the experiences and challenges faced by individuals and families affected by this rare genetic disorder. By portraying a message of hope and advocating for support and understanding, Vanda Pharmaceuticals has taken a significant step towards building a community that uplifts and supports those with SMS.

Vanda Pharmaceuticals TV commercial - Smith-Magenis Syndrome produced for Vanda Pharmaceuticals was first shown on television on November 15, 2021.

Frequently Asked Questions about vanda pharmaceuticals tv spot, 'smith-magenis syndrome'

Smith-Magenis syndrome (SMS) is a complex developmental disorder that affects multiple organ systems of the body. The disorder is characterized by a pattern of abnormalities that are present at birth (congenital) as well as behavioral and cognitive problems.

Tradipitant (VLY-686, LY-686017) is under development for the treatment of gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor.

Smith-Magenis syndrome is usually not inherited. This condition typically results from a chromosomal deletion or an RAI1 gene variant that occurs during the formation of reproductive cells (eggs or sperm) or in early fetal development.

A chromosome deletion (a portion containing the RAI1 gene) or a mutation of the RAI1 gene itself causes Smith-Magenis syndrome. Nearly 90% of children diagnosed with the condition are missing the RAI1 gene, which is part of the short arm (p) of chromosome 17 (17q11.

Tradipitant overview Tradipitant (VLY-686, LY-686017) is under development for the treatment of gastroparesis, functional dyspepsia and motion sickness. It is administered through oral route as a capsule. The drug candidate is a new chemical entity that targets neurokinin-1 (NK-1) receptor.

That said, many studies show that as a whole, Dramamine is more effective at preventing motion sickness, though it is less convenient given the dosing. Another option is scopolamine, which is commonly known as the round patch placed behind one's ear.

SMS provides simple and cost-effective way of communicating with customers, but the benefits go far beyond that. Which is exactly why it remains an essential part of communication and marketing strategies. SMS is a simple technology initially used to facilitate person-to-person (P2P) communication.

SMS technology originated from radio telegraphy in radio memo pagers that used standardized phone protocols. These were defined in 1986 as part of the Global System for Mobile Communications (GSM) series of standards.

Summary. Smith-Magenis syndrome (SMS) is a developmental disorder that affects many parts of the body. The major features of this condition include mild to moderate intellectual disability, delayed speech and language skills, distinctive facial features, sleep disturbances, and behavioral problems.

Promising investigational pharmacologic therapies include relamorelin, prucalopride, and aprepitant. A novel endoscopic therapy is gastric peroral endoscopic pyloromyotomy, which is associated with improved gastric emptying.

Metoclopramide: This medicine increases the movements in your digestive system, helping the food to pass through more quickly and efficiently. This is the only medication in the United States that is FDA approved to treat gastroparesis. However, in some patients it may cause movement disorders.

Treatment for motion sickness Medications either calm the nerves of the inner ear or soothe the brain's vomiting centre. However, nearly all motion sickness pills are most effective if they are taken before you feel sick. Some motion sickness pills may cause drowsiness as a side effect.

Videos

Watch Vanda Pharmaceuticals TV Commercial, 'Smith-Magenis Syndrome'

Unfortunately we were unable to find any suitable videos in the public domain. Perhaps the video of this TV commercial has not been preserved. If you know the link to this commercial, you can send it to us using a special form.

Actors

Actors who starred in Vanda Pharmaceuticals TV Spot, 'Smith-Magenis Syndrome'

Brian Scott Mitchell photo
TV commercials

Similar commercials

Bass Pro Shops Summer Savings TV Spot, 'Men's Henleys and Ascend Dash Packs'
Vanda Pharmaceuticals TV Spot, 'Delayed Sleep Study'
Root Insurance TV Spot, 'All About You'
Bass Pro Shops Go Outdoors Sale TV Spot, 'Eclipse Tent and Kayaks'
Deep Silver TV Spot, 'Metro Exodus'
1061 February 5, 2019
Deep Silver TV Spot, 'Homefront: The Revolution'
Root Insurance TV Spot, 'Save Hundreds'
Vanda Pharmaceuticals TV Spot, 'Gastroparesis Study'
Deep Silver TV Spot, 'Saints Row IV'
Vanda Pharmaceuticals TV Spot, 'Akathisia'
Root Insurance TV Spot, 'Customize Your Coverage'
Root Insurance TV Spot, 'Control Your Rates: Better Price'